Esmolol – do we need short-acting beta-blockers? Review article
Article Sidebar
Published:
Sep 30, 2010
Keywords:
esmolol, short-acting beta-blockers
Main Article Content
Abstract
Esmolol belongs to the II generation of β-blockers. However, pharmacokinetic and pharmacodynamic parameters of this drug, differ it from the other cardioselective β-blockers. Esmolol is a β1-adrenoreceptor antagonist administered only intravenously, with rapid onset and short duration of action. It may be preferred in the treatment of supraventricular tachycardia, rhythm control in atrial fibrillation or flutter and in intervention reducing of blood pressure in hypertensive patients. Drug is particularly suitable in perioperative period.
Article Details
How to Cite
Kuch , M., Światowiec , A., & Wsół, A. (2010). Esmolol – do we need short-acting beta-blockers?. Medycyna Faktow (J EBM), 3(3(8), 27-33. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2574
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Lopez-Sendon J., Swedberg K., McMurray J. et al.: Expert consensus document on beta-adrenergic receptor blockers. Eur. Heart J. 2004; 25: 1341-1362.
2. Filipiak K.J., Grabowski M., Opolski G.: Farmakologia kliniczna leków beta-adrenolitycznych. W: Leki beta-adrenolityczne w chorobach układu sercowo-naczyniowego. Grodzicki T., Januszewicz A., Opolski G. (red.). Via Medica, Gdańsk 2004: 1-42.
3. Esmocard. Charakterystyka Produktu Leczniczego (ChPL). Podmiot odpowiedzialny: Orpha-Devel Handel und Vertriebs GmbH. Polska 2008.
4. Filipiak K.J., Stępińska J., Mamcarz A., Opolski G.: Miejsce nowoczesnych dożylnych β-adrenolityków na oddziałach kardiologicznych – zasady stosowania i wskazania dla esmololu. Choroby Serca i Naczyń 2008; 5: 204-208.
5. Varon J.: Treatment of acute severe hypertension: current and newer agents. Drugs 2008; 68 (3): 283-97.
6. Wiest D.: Esmolol – a review of its therapeutic efficacy and pharmacokinetic characteristics. Clin. Pharmacokinet. 1995; 28: 190-200.
7. Lowenthal D.T., Porter S., Saris S.D. et al.: Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am. J. Cardiol. 1985; 56: 14F-18F.
8. Hohnloser S.H., Meinertz T., Klingernheben T. et al.: Usefulness of esmolol in unstable angina pectoris. Am. J. Cardiol. 1991; 67: 1319-1323.
9. Williams M.J.S., Low C.J.S., Wilkins G.T., Stewart R.A.H.: Randomised comparison of the effects of nicardipine and esmolol on coronary artery wall stress: implications for the risk of plaque rupture. Heart 2000; 84: 377-382.
10. Labovitz A.J., Barth C., Castello R. et al.: Attenuation of myocardial ischemia during coronary occlusion by ultrashort-acting beta adrenergic blockade. Am. Heart J. 1991; 121: 1347-1352.
11. Das G., Tschida V., Gray R.I. et al.: Efficacy of Esmolol in the Treatment and Transfer of Patients with Supraventricular Tachyarrhythmias to Alternate Oral Antiarrhythmic Agents. J. Clin. Pharmacol. 1988; 28: 746-750.
12. Platia E.V., Michelson E.L., Porterfield J.K. et al.: Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flatter. Am. J. Cardiol. 1989; 63: 925-929.
13. Andreson S., Blanski L., Byrd R.: Comparison of the efficacy and safety of esmolol, a short-acting beta-blocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am. Heart J. 1986; 111: 42-48.
14. Abrams J., Anderson S., DiBianco R.: Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial. Am. Heart J. 1985; 110: 913-922.
15. Gray R.J., Bateman T., Czer L.S.: Esmolol: a new ultra-short-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. JACC 1985; 5: 1451-1456.
16. Mooss A.N., Hilleman D.E., Mohiuddin S.M., Hunter C.B.: Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy. Ann. Pharmacother. 1994; 28: 701-703.
17. Kirshenbaum J.M., Kloner R.F., McGowan N., Antman E.M.: Use of an ultrashortacting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy. JACC 1988; 12: 733-780.
18. Mitchell R.G., Stoddard M.F., Ben-Yehuda O. et al.; for the EMIT Investigators: The Multicenter Study of Expanded Utilization of Intravenous Beta-Blocker Therapy in Acute Ischemic Syndromes: The Esmolol Myocardial Ischemia Trial (EMIT). Am. Heart J. 2002; 144: 107-112.
19. Sheppard S., Eagle C.J., Strunin L.: A bolus dose of esmolol attenuates tachycardia and hypertension after tracheal intubation. Can. J. Anaesth. 1990; 37: 202-5.
20. Oxorn D., Knox J.W., Hill J.: Bolus doses of esmolol for the prevention of perioperative hypertension and tachycardia. Can. J. Anaesth. 1990; 37: 206-9.
21. Miller D.R., Martineau R.J., Hill J.: Bolus administration of esmolol for controlling the haemodynamic response to tracheal intubation: the Canadian multicentre trial. Can. J. Anaesth. 1991; 38: 849-58.
22. Gray R.J., Bateman T.M., Czer L.S. et al.: Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension. Am. J. Cardiol. 1987; 59: 887-91.
23. Muzzi D.A., Black S., Losasso T.J. et al.: Labetalol and esmolol in the control of hypertension after intracranial surgery. Anesth. Analg. 1990; 70: 68-71.
24. Gibson B.E., Black S., Maass L. et al.: Esmolol for the control of hypertension after neurologic surgery. Clin. Pharmacol. Ther. 1988; 44: 650-3.
25. Varon J.: The diagnosis and treatment of hypertensive crisis. Postgrad. Med. 2009; 121 (1): 5-12.
26. Goldberg M.E., Waever F.A.: Strategies for managing perioperative hypertension. Crit. Care Clin. 2007; 23 (suppl 1): 1-21.
27. Degertekin M., Gemici G., Kaya Z., et al.: Safety and efficacy of patient preparation with intravenous esmolol before 64-slice computed tomography coronary angiography. Coronary Artery Disease 2008;19:33-36.
28. Fuster V., Ryden L.E., Cannom D.S. et al.: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Europace 2006; 8: 651-745.
29. Erbel R., Alfonso F., Boileau C. et al.: Diagnosis and management of aortic dissection. Recommendations of the Task Force on Aortic Dissection, European Society of Cardiology. Eur. Heart J. 2001; 22: 1642-1681.
30. Rhoney D., Peacock W.F.: Intravenous therapy for hypertensive emergencies, part 1. Am. J. Health Syst. Pharm. 2009; 66 (15): 1343-52.
31. Rhoney D., Peacock W.F.: Intravenous therapy for hypertensive emergencies, part 2. Am. J. Health Syst. Pharm. 2009; 66 (16): 1448-57.
2. Filipiak K.J., Grabowski M., Opolski G.: Farmakologia kliniczna leków beta-adrenolitycznych. W: Leki beta-adrenolityczne w chorobach układu sercowo-naczyniowego. Grodzicki T., Januszewicz A., Opolski G. (red.). Via Medica, Gdańsk 2004: 1-42.
3. Esmocard. Charakterystyka Produktu Leczniczego (ChPL). Podmiot odpowiedzialny: Orpha-Devel Handel und Vertriebs GmbH. Polska 2008.
4. Filipiak K.J., Stępińska J., Mamcarz A., Opolski G.: Miejsce nowoczesnych dożylnych β-adrenolityków na oddziałach kardiologicznych – zasady stosowania i wskazania dla esmololu. Choroby Serca i Naczyń 2008; 5: 204-208.
5. Varon J.: Treatment of acute severe hypertension: current and newer agents. Drugs 2008; 68 (3): 283-97.
6. Wiest D.: Esmolol – a review of its therapeutic efficacy and pharmacokinetic characteristics. Clin. Pharmacokinet. 1995; 28: 190-200.
7. Lowenthal D.T., Porter S., Saris S.D. et al.: Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am. J. Cardiol. 1985; 56: 14F-18F.
8. Hohnloser S.H., Meinertz T., Klingernheben T. et al.: Usefulness of esmolol in unstable angina pectoris. Am. J. Cardiol. 1991; 67: 1319-1323.
9. Williams M.J.S., Low C.J.S., Wilkins G.T., Stewart R.A.H.: Randomised comparison of the effects of nicardipine and esmolol on coronary artery wall stress: implications for the risk of plaque rupture. Heart 2000; 84: 377-382.
10. Labovitz A.J., Barth C., Castello R. et al.: Attenuation of myocardial ischemia during coronary occlusion by ultrashort-acting beta adrenergic blockade. Am. Heart J. 1991; 121: 1347-1352.
11. Das G., Tschida V., Gray R.I. et al.: Efficacy of Esmolol in the Treatment and Transfer of Patients with Supraventricular Tachyarrhythmias to Alternate Oral Antiarrhythmic Agents. J. Clin. Pharmacol. 1988; 28: 746-750.
12. Platia E.V., Michelson E.L., Porterfield J.K. et al.: Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flatter. Am. J. Cardiol. 1989; 63: 925-929.
13. Andreson S., Blanski L., Byrd R.: Comparison of the efficacy and safety of esmolol, a short-acting beta-blocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am. Heart J. 1986; 111: 42-48.
14. Abrams J., Anderson S., DiBianco R.: Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial. Am. Heart J. 1985; 110: 913-922.
15. Gray R.J., Bateman T., Czer L.S.: Esmolol: a new ultra-short-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. JACC 1985; 5: 1451-1456.
16. Mooss A.N., Hilleman D.E., Mohiuddin S.M., Hunter C.B.: Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy. Ann. Pharmacother. 1994; 28: 701-703.
17. Kirshenbaum J.M., Kloner R.F., McGowan N., Antman E.M.: Use of an ultrashortacting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy. JACC 1988; 12: 733-780.
18. Mitchell R.G., Stoddard M.F., Ben-Yehuda O. et al.; for the EMIT Investigators: The Multicenter Study of Expanded Utilization of Intravenous Beta-Blocker Therapy in Acute Ischemic Syndromes: The Esmolol Myocardial Ischemia Trial (EMIT). Am. Heart J. 2002; 144: 107-112.
19. Sheppard S., Eagle C.J., Strunin L.: A bolus dose of esmolol attenuates tachycardia and hypertension after tracheal intubation. Can. J. Anaesth. 1990; 37: 202-5.
20. Oxorn D., Knox J.W., Hill J.: Bolus doses of esmolol for the prevention of perioperative hypertension and tachycardia. Can. J. Anaesth. 1990; 37: 206-9.
21. Miller D.R., Martineau R.J., Hill J.: Bolus administration of esmolol for controlling the haemodynamic response to tracheal intubation: the Canadian multicentre trial. Can. J. Anaesth. 1991; 38: 849-58.
22. Gray R.J., Bateman T.M., Czer L.S. et al.: Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension. Am. J. Cardiol. 1987; 59: 887-91.
23. Muzzi D.A., Black S., Losasso T.J. et al.: Labetalol and esmolol in the control of hypertension after intracranial surgery. Anesth. Analg. 1990; 70: 68-71.
24. Gibson B.E., Black S., Maass L. et al.: Esmolol for the control of hypertension after neurologic surgery. Clin. Pharmacol. Ther. 1988; 44: 650-3.
25. Varon J.: The diagnosis and treatment of hypertensive crisis. Postgrad. Med. 2009; 121 (1): 5-12.
26. Goldberg M.E., Waever F.A.: Strategies for managing perioperative hypertension. Crit. Care Clin. 2007; 23 (suppl 1): 1-21.
27. Degertekin M., Gemici G., Kaya Z., et al.: Safety and efficacy of patient preparation with intravenous esmolol before 64-slice computed tomography coronary angiography. Coronary Artery Disease 2008;19:33-36.
28. Fuster V., Ryden L.E., Cannom D.S. et al.: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Europace 2006; 8: 651-745.
29. Erbel R., Alfonso F., Boileau C. et al.: Diagnosis and management of aortic dissection. Recommendations of the Task Force on Aortic Dissection, European Society of Cardiology. Eur. Heart J. 2001; 22: 1642-1681.
30. Rhoney D., Peacock W.F.: Intravenous therapy for hypertensive emergencies, part 1. Am. J. Health Syst. Pharm. 2009; 66 (15): 1343-52.
31. Rhoney D., Peacock W.F.: Intravenous therapy for hypertensive emergencies, part 2. Am. J. Health Syst. Pharm. 2009; 66 (16): 1448-57.